Number: RTOG 0839 Principal Investigator: Robinson, Clifford
Title: Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Phase: II Disease Site: Lung
Participating Site(s):
Main Campus
Map and Directions
West County
Map and Directions
Contact: 800-600-3606 or

This study will compare the effects, good and/or bad, of adding panitumumab to chemotherapy and radiation therapy. In this study, you will get chemotherapy and radiation OR radiation, chemotherapy, and panitumumab.
Panitumumab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. It has been approved by the FDA as a single agent for the treatment of epidermal growth factor receptor (EGFR) expression in patients with colorectal cancer whose disease has progressed after prior chemotherapy. Panitumumab has not yet been approved as a treatment for patients with lung cancer, as it has not yet been shown to be effective for the treatment of lung cancer. It is considered experimental in this study.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)